Showing results (141-150 of 183) with videos related to
Sort By:
Pageof 19
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 18, 2020
Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naive Adults Living With HIV-1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58)Arkaitz Imaz, Juan M Tiraboschi, Jordi Niubó, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|February 26, 2008
Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain)Angeles Jaén, Anna Esteve, Josep M Miró, et al.Medicina Clinica|April 26, 2005
[Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project]Angeles Jaén, Jordi Casabona, Anna Esteve, et al.Enfermedades Infecciosas Y Microbiologia Clinica|April 25, 2012
[Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012]Antonio Javier Blasco, José Ramón Arribas, Vicente Boix, et al.Journal of the International AIDS Society|November 15, 2014
ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR studyDaniel Podzamczer, Nerea Rozas, Pere Domingo, et al.Enfermedades Infecciosas Y Microbiologia Clinica|August 24, 2013
[Analysis of costs and cost-effectiveness of preferred GESIDA/National AIDS Plan regimens for initial antiretroviral therapy in human immunodeficiency virus infected adult patients in 2013]Antonio Javier Blasco, Josep M Llibre, José Ramón Arribas, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 5, 2011
Restoration of T cell responses to toxoplasma gondii after successful combined antiretroviral therapy in patients with AIDS with previous toxoplasmic encephalitisMarylène Lejeune, José M Miró, Elisa De Lazzari, et al.The New England Journal of Medicine|September 12, 2003
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infectionEsteban Martínez, Juan A Arnaiz, Daniel Podzamczer, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 13, 2014
Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trialEsteban Martinez, Ana Gonzalez-Cordon, Elena Ferrer, et al.The Lancet. HIV|March 6, 2017
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority studyChloe Orkin, Edwin DeJesus, Moti Ramgopal, et al.Pageof 19